首页> 外文期刊>Coronary artery disease >Prasugrel versus clopidogrel for residual thrombus burden in patients with ST-segment elevation myocardial infarction: an optical coherence tomography study
【24h】

Prasugrel versus clopidogrel for residual thrombus burden in patients with ST-segment elevation myocardial infarction: an optical coherence tomography study

机译:普拉苏格雷与氯吡格血管患者对患者的ST段抬高心肌梗死患者:光学相干断层扫描研究

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

BackgroundPrasugrel was shown to inhibit platelet activity more rapidly and consistently than clopidogrel. We compared the effects of prasugrel and clopidogrel on residual thrombus burden assessed by optical coherence tomography after stent implantation in patients with ST-segment elevation myocardial infarction (STEMI).Patients and methodsA total of 76 patients with STEMI undergoing percutaneous coronary intervention (PCI) within 12h after the onset were retrospectively enrolled. Of them, 34 patients were treated with prasugrel (loading dose, 20mg) and the remaining 42 with clopidogrel (loading dose, 300mg). Stent volume and in-stent thrombus volume were assessed by post-PCI optical coherence tomography.ResultsBaseline clinical characteristics, angiographic findings, and PCI procedure did not differ between the two groups. There was no difference in in-stent volume between patients with prasugrel and clopidogrel [169 (134-214) versus 166 (128-210) mm(3), P=0.83]. Patients with prasugrel had a significantly reduced in-stent thrombus volume compared with those with clopidogrel [0.59 (0.16-1.09) vs. 1.08 (0.32-2.30) mm(3), P=0.03]. The mean area and maximum area of in-stent thrombus were also significantly smaller in prasugrel than in clopidogrel group [0.03 (0.01-0.05) vs. 0.05 (0.01-0.10) mm(2), P=0.04, and 0.45 (0.27-0.75) vs. 0.77 (0.34-1.23) mm(2), P=0.03, respectively].ConclusionPrasugrel more effectively reduced residual thrombus burden after stent implantation in patients with STEMI, indicating a faster and more potent platelet inhibitory effect of prasugrel compared with clopidogrel.
机译:背景蛋白被显示为比氯吡格雷更快且始终抑制血小板活性。比较了普拉布雷和氯吡格雷在ST段抬高心肌梗死(STEMI)患者支架植入术后光相干断层扫描对剩余血栓负担的影响在发病次追溯注册后12h。其中,用普拉布雷(负载剂量,20mg)和剩余的42例含有氯吡格雷(负载剂量,300mg)治疗34名患者。通过后PCI光学相干断层扫描来评估支架体积和支架内血栓体积。两组之间的诊断临床特征,血管造影表明和PCI程序在两组之间没有区别。普拉布雷和氯吡格雷患者与166(128-210)mm(3),p = 0.83]之间没有差异。与氯吡格雷的那些相比,普拉布雷的患者具有显着减少的血栓体积[0.59(0.16-1.09)与1.08(0.32-2.30)mm(3),p = 0.03]。普拉布雷的平均面积和最大面积也比氯吡格雷基团在普拉氏菌中显着较小[0.03(0.01-0.05)与0.05(0.01-0.10)mm(2),p = 0.04和0.45(0.27- 0.75)与0.77(0.34-1.23)mm(2),p = 0.03分别]。结论产粒子在STEMI患者的支架植入后更有效地降低了残留的血栓负荷,表明普拉苏格雷的速度更快,更有效的血小板抑制作用氯吡格雷。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号